TrovaGene (TROV) Sees Strong Trading Volume
TrovaGene Inc (NASDAQ:TROV) shares saw unusually-strong trading volume on Thursday . Approximately 1,477,200 shares were traded during trading, an increase of 185% from the previous session’s volume of 517,912 shares.The stock last traded at $0.83 and had previously closed at $0.81.
A number of research analysts recently issued reports on TROV shares. Maxim Group upgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a research report on Friday, June 15th. Zacks Investment Research upgraded shares of TrovaGene from a “sell” rating to a “hold” rating in a research report on Saturday, August 18th. ValuEngine upgraded shares of TrovaGene from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, HC Wainwright set a $7.00 target price on shares of TrovaGene and gave the company a “buy” rating in a research report on Monday, June 4th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. TrovaGene currently has a consensus rating of “Hold” and a consensus target price of $19.17.
The stock has a market cap of $14.35 million, a PE ratio of -0.13 and a beta of -0.14.
An institutional investor recently raised its position in TrovaGene stock. Renaissance Technologies LLC grew its position in TrovaGene Inc (NASDAQ:TROV) by 58.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 203,802 shares of the medical research company’s stock after acquiring an additional 75,131 shares during the period. Renaissance Technologies LLC owned about 1.15% of TrovaGene worth $157,000 at the end of the most recent quarter. 8.89% of the stock is owned by institutional investors.
TrovaGene Company Profile (NASDAQ:TROV)
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.